New combo tackles Drug-Resistant lung cancer

NCT ID NCT04001777

Ongoing Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called APG-1252 combined with the standard pill osimertinib in 80 people with EGFR-positive non-small cell lung cancer that has stopped responding to other targeted therapies. The goal is to find a safe dose and see if the combination can shrink tumors. The study includes patients who have already tried several treatments, including osimertinib itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APG-1252 (injection) and osimertinib (tablet)
What this could lead to: If successful, this combination could offer a new treatment option for people with EGFR-positive lung cancer whose cancer has stopped responding to standard targeted therapies.
What could go wrong: This is an early Phase 1 trial with only 80 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR POSITIVE NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

First Hospital of Jilin University

Changchun, Jilin, China
Henan Provincial people's Hospital

Zhengzhou, Henan, China
Jilin Provincial Cancer Hospital

Changchun, Jilin, China
Sun-Yat Sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.